A phase 3b trial showed adjuvanted RSVPreF3 vaccination was immunogenic and safe for younger adults with chronic conditions at increased risk for RSV disease.
Median 4-week preF IgG fold rise was 4.21; 61% of participants achieved seroconversion. (HealthDay News) — For immunocompromised individuals, antibody response to respiratory syncytial virus (RSV) ...
RA patients on upadacitinib and methotrexate showed robust antibody and T-cell responses to the recombinant zoster vaccine over 60 weeks. The vaccine maintained a satisfactory humoral response in 71.4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results